<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00344799</url>
  </required_header>
  <id_info>
    <org_study_id>UCLA IRB#04-12-084</org_study_id>
    <secondary_id>11-000847</secondary_id>
    <nct_id>NCT00344799</nct_id>
  </id_info>
  <brief_title>Cytogenetic Study of Ocular Melanoma</brief_title>
  <official_title>Molecular and Cytogenetic Studies of Ocular Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <brief_summary>
    <textblock>
      Patients who are diagnosed with choroidal melanoma and undergo I-125 plaque or enucleation&#xD;
      surgery consent to participate in the study. A tumor sample taken during surgery is studied&#xD;
      in the lab for genetic features. These features and features of subjects' clinical course are&#xD;
      recorded. Analysis of the data may identify genetic features that are indicative of&#xD;
      prognostic factors including risk of metastasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Jules Stein Eye Institute Ocular Melanoma Research Group is conducting cytogenetic&#xD;
      studies of choroidal melanoma to improve the screening of biopsy samples of choroidal&#xD;
      melanoma through cytogenetic analysis. Our goal is to identify molecular probes that&#xD;
      specifically target regions of chromosomes that undergo changes characteristic of metastatic&#xD;
      choroidal melanoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2005</start_date>
  <completion_date type="Actual">October 23, 2020</completion_date>
  <primary_completion_date type="Actual">October 23, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">95</enrollment>
  <condition>Choroidal Melanoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have been diagnosed with ocular melanoma, and underwent melanoma treatment at&#xD;
        our facility.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with diagnosis of ocular melanoma&#xD;
&#xD;
          2. Patient with local treatment plan for ocular melanoma- plaque brachytherapy or&#xD;
             enucleation&#xD;
&#xD;
          3. Patient 18 years of age or older&#xD;
&#xD;
          4. Archival enucleation specimens with diagnosis of ocular melanoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who refuses local melanoma treatment&#xD;
&#xD;
          2. Patient who refuses to participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tara M McCannel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jules Stein Eye Institute, UCLA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bradley R Straatsma, MD, JD</last_name>
    <role>Study Director</role>
    <affiliation>Jules Stein Eye Institute, UCLA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynn Gordon, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Jules Stein Eye Institute, UCLA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ben Glasgow, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jules Stein Eye Institute, UCLA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nagesh P Rao, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UCLA Pathology and Laboratory Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jules Stein Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 26, 2006</study_first_submitted>
  <study_first_submitted_qc>June 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2006</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Choroidal Melanoma</keyword>
  <keyword>Choroidal Malignant Melanoma</keyword>
  <keyword>Ocular Melanoma</keyword>
  <keyword>Uveal Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

